These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24606320)

  • 21. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
    Mártinez JM; Pulido LB; Bellido CB; Usero DD; Aguilar LT; Moreno JL; Artacho GS; Díez-Canedo JS; Gómez LM; Bravo MA
    Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation.
    Steg RE; Kessinger A; Wszolek ZK
    Bone Marrow Transplant; 1999 May; 23(9):959-62. PubMed ID: 10338054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor.
    Sugiyama K; Tsukaguchi M; Toyama A; Satoh H; Saito K; Nakagawa Y; Takahashi K; Tanaka S; Onda K; Hirano T
    Exp Clin Transplant; 2014 Jun; 12(3):195-9. PubMed ID: 24907718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunosuppression after liver transplant, now and in future].
    Trunečka P
    Vnitr Lek; 2013 Aug; 59(8):671-7. PubMed ID: 24007221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database.
    Watt KD; Dierkhising R; Heimbach JK; Charlton MR
    Liver Transpl; 2012 Sep; 18(9):1029-36. PubMed ID: 22641474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation.
    Yang YJ; Li LX; He Q; Fan H; Jin ZK; Lang R; Kou JT; Li P; Xie DH; Chen DZ
    Hepatobiliary Pancreat Dis Int; 2007 Aug; 6(4):376-8. PubMed ID: 17690032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
    Toso C; Meeberg GA; Bigam DL; Oberholzer J; Shapiro AM; Gutfreund K; Ma MM; Mason AL; Wong WW; Bain VG; Kneteman NM
    Transplantation; 2007 May; 83(9):1162-8. PubMed ID: 17496530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T; Argudo A; Peña-Cala MC
    Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimating the contribution of everolimus to immunosuppressive efficacy when combined with tacrolimus in liver transplantation: a model-based approach.
    Dumortier T; Looby M; Luttringer O; Heimann G; Klupp J; Junge G; Witte S; VanValen R; Stanski D
    Clin Pharmacol Ther; 2015 Apr; 97(4):411-8. PubMed ID: 25669933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
    Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
    Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
    Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus in liver transplantation.
    Trotter JF; Lizardo-Sanchez L
    Curr Opin Organ Transplant; 2014 Dec; 19(6):578-82. PubMed ID: 25254569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful retransplantation using rapamycin in a patient with previous calcineurin inhibitor-induced posterior leukoencephalopathy syndrome.
    Afzali B; Goldsmith DJ
    Clin Nephrol; 2003 Mar; 59(3):225-8. PubMed ID: 12653269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection.
    Yoshida EM; Lilly LB; Marotta PJ; Mason AL; Bilodeau M; Vaillancourt M
    Ann Hepatol; 2013; 12(2):282-93. PubMed ID: 23396740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy.
    Manousou P; Samonakis D; Cholongitas E; Patch D; O'Beirne J; Dhillon AP; Rolles K; McCormick A; Hayes P; Burroughs AK
    Liver Transpl; 2009 Dec; 15(12):1783-91. PubMed ID: 19938143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five-year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study.
    Saliba F; Duvoux C; Dharancy S; Dumortier J; Calmus Y; Gugenheim J; Kamar N; Salamé E; Neau-Cransac M; Vanlemmens C; Durand F; Pageaux GP; Hardwigsen J; Benkhatar Y; Derquenne F; Conti F
    Liver Int; 2022 Nov; 42(11):2513-2523. PubMed ID: 35962772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.
    Kneteman NM; Oberholzer J; Al Saghier M; Meeberg GA; Blitz M; Ma MM; Wong WW; Gutfreund K; Mason AL; Jewell LD; Shapiro AM; Bain VG; Bigam DL
    Liver Transpl; 2004 Oct; 10(10):1301-11. PubMed ID: 15376305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fulminant Acute Respiratory Distress Syndrome After Calcineurin Inhibitor-belatacept Conversion in a Lung Transplant Recipient.
    Brugière O; Cazes A; Champion L; Debray MP; Mourin G; Crestani B; Sroussi D; Bunel V; Jebrak G; Dauriat G; Castier Y; Mordant P; Lortat-Jacob B; Jean-Baptiste S; Bouadma L; Mal H; Thabut G
    Transplantation; 2018 Jun; 102(6):e255-e256. PubMed ID: 29509571
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation.
    Alamo JM; Barrera L; Casado MD; Bernal C; Marin LM; Suarez G; Sanchez-Moreno L; Jimenez R; Suarez-Grau JM; Sousa JM; Cordero E; Gomez-Bravo MA
    Transplant Proc; 2009; 41(6):2181-3. PubMed ID: 19715866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.